Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.53
(-1.91%)
USD 0.53
(-1.91%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 46.33 Million USD | 466.27% |
| 2022 | 8.18 Million USD | -7.37% |
| 2021 | 8.83 Million USD | 22.06% |
| 2020 | 7.23 Million USD | 0.66% |
| 2019 | 7.18 Million USD | 89.11% |
| 2018 | 3.8 Million USD | 1.6% |
| 2017 | 3.74 Million USD | 40.33% |
| 2016 | 2.66 Million USD | 14.26% |
| 2015 | 2.33 Million USD | 105.87% |
| 2014 | 1.13 Million USD | 31.97% |
| 2013 | 858.96 Thousand USD | 917.41% |
| 2012 | 84.42 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.05 Million USD | -89.1% |
| 2024 Q2 | 5.26 Million USD | 4.16% |
| 2023 Q4 | 46.33 Million USD | 597.67% |
| 2023 Q1 | 5.63 Million USD | -31.1% |
| 2023 FY | 46.33 Million USD | 466.27% |
| 2023 Q2 | 6.17 Million USD | 9.47% |
| 2023 Q3 | 6.64 Million USD | 7.62% |
| 2022 FY | 8.18 Million USD | -7.37% |
| 2022 Q3 | 8.92 Million USD | -6.69% |
| 2022 Q2 | 9.56 Million USD | 18.07% |
| 2022 Q4 | 8.18 Million USD | -8.34% |
| 2022 Q1 | 8.1 Million USD | -8.26% |
| 2021 FY | 8.83 Million USD | 22.06% |
| 2021 Q1 | 5.79 Million USD | -19.93% |
| 2021 Q2 | 7.06 Million USD | 21.97% |
| 2021 Q4 | 8.83 Million USD | 1.17% |
| 2021 Q3 | 8.73 Million USD | 23.53% |
| 2020 Q3 | 6.6 Million USD | 5.41% |
| 2020 FY | 7.23 Million USD | 0.66% |
| 2020 Q1 | 6.51 Million USD | -9.44% |
| 2020 Q2 | 6.26 Million USD | -3.81% |
| 2020 Q4 | 7.23 Million USD | 9.63% |
| 2019 Q3 | 6.83 Million USD | -12.33% |
| 2019 Q4 | 7.18 Million USD | 5.17% |
| 2019 FY | 7.18 Million USD | 89.11% |
| 2019 Q1 | 7.56 Million USD | 99.04% |
| 2019 Q2 | 7.79 Million USD | 3.04% |
| 2018 Q1 | 3.05 Million USD | -18.33% |
| 2018 Q4 | 3.8 Million USD | -7.54% |
| 2018 FY | 3.8 Million USD | 1.6% |
| 2018 Q2 | 3.51 Million USD | 15.1% |
| 2018 Q3 | 4.11 Million USD | 16.9% |
| 2017 Q2 | 2.59 Million USD | -18.29% |
| 2017 FY | 3.74 Million USD | 40.33% |
| 2017 Q4 | 3.74 Million USD | 0.07% |
| 2017 Q3 | 3.73 Million USD | 44.27% |
| 2017 Q1 | 3.17 Million USD | 18.95% |
| 2016 Q2 | 2.56 Million USD | 1.67% |
| 2016 Q4 | 2.66 Million USD | 3.16% |
| 2016 FY | 2.66 Million USD | 14.26% |
| 2016 Q3 | 2.58 Million USD | 0.68% |
| 2016 Q1 | 2.52 Million USD | 8.21% |
| 2015 FY | 2.33 Million USD | 105.87% |
| 2015 Q3 | 2.9 Million USD | -10.06% |
| 2015 Q2 | 3.23 Million USD | -5.04% |
| 2015 Q1 | 3.4 Million USD | 200.37% |
| 2015 Q4 | 2.33 Million USD | -19.74% |
| 2014 Q1 | 716.98 Thousand USD | -16.53% |
| 2014 FY | 1.13 Million USD | 31.97% |
| 2014 Q4 | 1.13 Million USD | 8.67% |
| 2014 Q3 | 1.04 Million USD | 15.16% |
| 2014 Q2 | 905.81 Thousand USD | 26.34% |
| 2013 Q2 | 316.44 Thousand USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 858.96 Thousand USD | 917.41% |
| 2013 Q3 | 502.33 Thousand USD | 58.74% |
| 2013 Q4 | 858.96 Thousand USD | 70.99% |
| 2012 FY | 84.42 Thousand USD | 0.0% |
| 2012 Q4 | 84.42 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -406.527% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1850.0% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 67.378% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | -2.809% |
| Azitra, Inc. | 2.2 Million USD | -2003.762% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -1136.839% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -608.338% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | -153.818% |
| CEL-SCI Corporation | 17.31 Million USD | -167.608% |
| iBio, Inc. | 7.41 Million USD | -525.263% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | -18.812% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -553.545% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -270.214% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -710.0% |
| NanoViricides, Inc. | 1.35 Million USD | -3309.834% |
| Oragenics, Inc. | 1.79 Million USD | -2476.604% |
| BiomX Inc. | 55.07 Million USD | 15.875% |
| BiomX Inc. | 55.07 Million USD | 15.875% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 8.912% |
| Palatin Technologies, Inc. | 10.85 Million USD | -326.875% |
| Scorpius Holdings, Inc. | 22.74 Million USD | -103.717% |